Management of chronic rhinosinusitis in CF  by Mainz, Jochen G. & Koitschev, Assen
Journal of Cystic Fibrosis Volume 8 Suppl 1 (2009) S10–S14
www.elsevier.com/locate/jcf
Management of chronic rhinosinusitis in CF ✩
Jochen G. Mainza,*, Assen Koitschevb
aCystic Fibrosis Centre, University Hospital of Jena, D-07740 Jena, Germany
bDepartment of Otolaryngology, University Hospital of Tubingen, D-72076 Tubingen, Germany
Abstract
Routine CF management often does not include upper airway (UAW) assessment although CFTR defects equally affect the sinonasal
mucosa. Up to 50% of CF patients have chronic rhinosinusitis (CRS) and/or nasal polyps, and almost 100% reveal UAW abnormalities on CT
scan. CRS impairs quality of life. UAW dysfunction in ﬁltering, humidifying, and warming inspired air affects lower airways and the UAW is
a potential site of ﬁrst colonization and a reservoir for opportunistic bacteria. Therefore, UAW pathology substantially affects overall health in
CF.
Standard treatments are scarce and mostly lack evidence. Nasal douche can remove mucus and crusts. Recently, delivery of dornase alfa
using a vibrating aerosol has shown potential as treatment for CF-related CRS. Surgery is indicated when conservative approaches fail but
postoperative relapse is frequent.
In summary, upper airway involvement in CF is undertreated and requires prospective investigation and an interdisciplinary consensus on
diagnosis and therapy.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Thirty years ago cystic ﬁbrosis (CF) regularly led to death
during the ﬁrst decade of life. Patients were severely mal-
nourished and, like today, the principal reason for reduced
life expectancy was pulmonary deterioration due to chronic
infection with opportunistic bacteria e.g. Pseudomonas aerug-
inosa (P.a.). Since then, standardised aggressive treatment
has improved life expectancy enormously. As a consequence,
“secondary symptoms” like upper airway (UAW) involvement
and its impact on the course of the disease and quality of life
(QoL) are coming into the focus of CF care.
The CFTR defect affects the upper airway mucosa like
the lower airways, so that the paranasal sinuses (PS) are
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almost universally involved in CF [1–3]. Rhinosinusitis
(RS) symptoms with or without nasal polyps are therefore a
hallmark of the disease. Predominant clinical signs are chronic
nasal congestion, rhinorrhoea with anterior or postnasal drip,
mouth breathing, anosmia, facial pain and sleep disorders
[4,5].
The self-reported incidence of RS symptoms in CF is as
low as 10% without speciﬁc questioning [6]. However, on
careful evaluation, up to half of patients suffer from chronic
rhinosinusitis (CRS) (>3 months of symptoms per year) [2–4]
and another third report intermittent RS symptoms. Indeed,
computed tomography (CT) scans of the PS are pathologic
in almost all patients, although this is sometimes limited
to hypoplastic frontal sinuses [7]. Thus, a high index of
suspicion and meticulous evaluation are needed to diagnose
symptoms and signs of sinonasal disease in CF.
2. Impact of rhinosinusitis on CF health
RS in CF is assumed to be the result of the underlying
CFTR defect and bacterial infection that lead to inﬂammation
and thickening of the sinus mucosa and hypersecretion of
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mucus. RS requires signiﬁcant health care resources due to
difﬁculties in treatment. The health burden it imposes is
generally high: in non-CF patients QoL measures of bodily
pain and social functioning are signiﬁcantly worse for CRS
patients than patients with congestive heart failure, angina,
chronic obstructive pulmonary disease (COPD) or back pain
[8].
Besides impairing QoL, CRS may inﬂuence CF-related
health much more than expected by causing nutritional
and bronchopulmonary problems. As the senses of smell
and taste are strongly correlated, olfactory disorders, which
are a frequent symptom of CRS, can aggravate nutritional
problems. Thus, CRS may negatively inﬂuence appetite [2]
and nutritional status in patients who must struggle to
consume up to 150% of the generally recommended calories
per day.
Pulmonary disease is still the primary cause of premature
death in most CF-patients [9]. In healthy airways more than
7000 L of air is inspired per day and is water-saturated up to
100%, ﬁltered and warmed to body temperature within one
passage through the airways [10]. Dysfunction of the UAW
results in bronchial inhalation of cold, dry and non-ﬁltered air,
which negatively affects lower airway (LAW) function and
increases hyper-reactivity as in asthma [11].
Chronic pulmonary infection with P.a. plays a central role
in the progression of CF lung disease. There is increasing
evidence that the UAW is a site of ﬁrst colonization and a
reservoir for chronic persistence of P.a. [12–14]; the same P.a.
strains are found in sputum and UAW specimens [13], and
the same P.a. clones have been identiﬁed in the sputum and
bronchoalveolar lavage ﬂuid of CF lung transplant patients
before and after they received presumably P.a.-free lungs [14].
These genetically identical bacteria are thought to originate
from the patients’ trachea or UAW. Recent studies have shown
the persistence of P.a. in human UAW as bioﬁlm-forming
units [15].
3. Assessment of UAW involvement in CF
Basic clinical assessment of the UAW can easily be per-
formed in a few minutes. The appearance of the epithelium
and the patient’s breathing pattern give some essential in-
formation about sinonasal status: mouth breathing indicates
nasal obstruction, often combined with thick purulent anterior
and posterior discharge (postnasal drip); broadening of the
nasal dorsum [1] may be the result of expanding sinonasal
polyposis during growth of the facial features.
An otoscope, routinely used by paediatricians for in-
spection of the tympanon, can be employed for anterior
rhinoscopy. Mucosal status, secretions or crusts can be as-
sessed, e.g. pale mucosa with transparent secretions indicates
allergic rhinitis, reddish mucosa indicates viral infection, and
purulent discharge indicates bacterial CRS. Pronounced poly-
posis can also be detected and the overall adequacy of UAW
ventilation can be assessed without special apparatus [1,5].
Little information is gained from plain radiographs and
the gold standard of sinonasal radiographic imaging is a CT
scan, especially for planning surgical interventions. Magnetic
resonance imaging (MRI) allows better differentiation of
mucosa, polyps and retained secretions than CT but does not
display osseous structures [16] and requires more time and
cost.
An ear, nose and throat (ENT) specialist should be con-
sulted at the latest when troublesome sinonasal symptoms
persist longer then 12 weeks. In fact, an annual ENT consulta-
tion is advisable but is most often not part of routine CF care.
On the other hand, only an ENT specialist with expertise in
CF can serve as a meaningful extension of a CF management
team. The ENT specialist should be proﬁcient with differential
diagnosis of CF-related RS, including recurrence rates and
responsiveness to therapeutic measures.
3.1. Conservative treatment
Therapeutic regimens for CF-related RS are scarce and of-
ten lack systematic evaluation. A recent European consensus
on rhinosinusitis and nasal polyps gives an extensive general
overview of conservative and surgical therapeutic options [5].
Conservative measures are regarded as the initial, less
aggressive step in treatment. Although there are some studies
concerning different conservative treatment modalities in non-
CF CRS patients, very few studies are focused on CF patients
and there is therefore very little evidence for the efﬁcacy
or dosage of medical treatments for CF-related RS [2]. This
presentation focuses on treatments which the authors consider
to be of special interest in CF patients.
3.1.1. Nasal saline irrigations
Nasal douches or saline sprays are usually applied as
an adjunct to medical treatment in order to remove secre-
tions and crusts from the upper airways. Physiologic saline
(0.9%) or buffered hypertonic saline (which additionally con-
tains NaHCO3 and K2SO4 as main components and sparse
amounts of other ions) is used. Nasal douche is commonly
performed while the soft palate is elevated, with 125 mL of
ﬂuid for each nostril [17]. A recent Cochrane review [18]
concludes that saline irrigation is better than no treatment
for improving symptoms and disease-speciﬁc quality of life
scores in non-CF patients. Although there is evidence that
moderately hypertonic solutions improve mucociliary clear-
ance, an advantage of hypertonic over isotonic saline on
symptoms is less evident. While there may be some added
clinical beneﬁt, this is balanced by patient intolerance. No
information can be provided regarding the delivery, dosage
frequency or volume of nasal lavage [18] and there are no
data regarding nasal application of hypertonic saline in CF
patients.
3.1.2. Nasal decongestants
Nasal decongestants (oxymetazoline, phenylephrine and
xylometazoline) decrease congestion of the inferior turbinate
[19] but do not directly affect the maxillary or ethmoid
sinuses. Rebound congestion may occur after use for more
then a week, causing physical dependence on the medication
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or iatrogenic rhinitis [20]. Thus, decongestants should be
applied only as short term medication in acute exacerbations
of RS.
3.1.3. Topical steroids
Long term administration of topical steroids is a standard
treatment for allergic CRS and eosinophil-dominated nasal
polyposis in adults and children [5]. Although CF-related
nasal polyps are histologically dominated by neutrophils,
which do not respond to steroids, positive effects on CF-
related nasal polyps have been reported in smaller studies [21,
22]. This may be the result of the common anti-inﬂammatory
effect of steroids. Larger obstructing polyps usually require
surgery [23]. We recommend the application of topical
steroids in perioperative care and in CF-related nasal polyps
but this ﬁeld requires further investigation.
3.1.4. Topical antibiotics
The effect of antibiotic treatments in acute and chronic RS
unrelated to CF has been evaluated in a Cochrane review [24].
Chronic airway infection in CF is a special entity involving
colonization with opportunistic bacteria e.g. Staphylococcus
aureus and P.a. Therefore, CF-speciﬁc therapeutic regimens
may be required.
Addition of antibiotics to the last portion of nasal lavage in
the postoperative care of CF patients has reduced recurrence
rates [13]. There are also reports of nasal inhalation of
antibiotics by non-CF [25] and CF [26] patients. However,
standard nebulisation techniques are generally not expected to
reach crucial areas in the UAW due to the narrowness of the
sinus oriﬁces. The novel PARI SINUS™ nebulizer designed
for sinonasal deposition could give a new perspective to this
ﬁeld (see below).
3.1.5. Macrolides
Macrolides with 14- and 15-membered rings down-regulate
immune and inﬂammatory responses and promote tissue re-
pair by inﬂuencing neutrophil chemotaxis and inﬁltration,
inﬂammatory cytokine production, mucus production, and the
transportability of airway secretions. This mechanism is dis-
tinct from their antimicrobial properties. The clinical beneﬁt
of macrolides in non-CF patients with CRS includes de-
creased nasal secretion and postnasal drip, and improvement
in nasal obstruction [27].
Azithromycin is commonly used to treat P.a.-related CF
lung disease. Long-term, prospective, double-blind placebo-
controlled (DBPC) clinical studies are required to establish
the utility of macrolides in the treatment of CF-related CRS
[28].
3.1.6. Ibuprofen
Recent studies describe the positive effect of chronic high-
dose ibuprofen treatment on the progression of lung disease
in children with CF [29]. A small series of CF patients
with nasal polyposis who received ibuprofen all reported
absence of nasal polyps at some point during treatment,
although 42% subsequently required endoscopic sinus surgery
for polyposis [30]. More testing is needed to determine if
ibuprofen ameliorates CF polyposis.
3.1.7. Dornase alfa
Dornase alfa reduces mucus viscoselasticity and promotes
mucus clearance by cleaving long-chain DNA, a viscous
substance that reaches high concentrations in CF airway
secretions as a result of neutrophilic degradation. Clinically,
it reduces the risk of pulmonary exacerbations and improves
FEV1 [31] as well as the annual rate of decline in lung
function [32,33] in CF patients over 5 years old.
A DBPC study in early postoperative CF-related CRS
reported that nasal symptoms were better controlled by
dornase alfa than by isotonic saline when inhaled using a
conventional nebuliser: there was signiﬁcant improvement in
rhinoscopic ﬁndings as well as FEV1 [34]. However, the
paranasal sinuses are cavities communicating with the nose
only via narrow ducts, and therefore surgical enlargement of
the oriﬁces is believed to be obligatory to permit conventional
nebulisers to deliver drugs to the sinus mucosa.
Aerosols can potentially enter sinus cavities when a
pressure gradient is induced by a vibrating air ﬂow [35]. This
principle was implemented in the PARI SINUS™, a novel
device that targets drug delivery to the PS via a pulsating
aerosol with a frequency of approximately 44.5 Hz [36]. In a
small (5 patients) DBPC cross-over pilot study we assessed
the suitability of endpoints for a larger trial of dornase alfa
delivered using the PARI SINUS™ as conservative therapy
for CF-related CRS. We found that dornase alfa signiﬁcantly
improved the Sino-Nasal Outcome Test-20 (SNOT-20) score,
a QoL measure speciﬁc for CRS symptoms [37]. Further
research will determine whether this novel conservative
approach fulﬁls its initial promise.
3.2. Surgical therapy
Therapy of chronic nasal obstruction in CF patients relies
heavily on surgical measures when conservative approaches
fail. In the short term, surgery leads to signiﬁcant improve-
ment of primary symptoms, e.g. nasal airway obstruction,
purulent nasal discharge and olfactory function, as well as
secondary symptoms, e.g. activity level [38]. However, these
beneﬁts persist in only half of the population [1,39], and
recur in 46–100% of patients within 2–4 years [40]. Re-
currence seems to be less frequent with more aggressive
surgery or with a combination of surgical and conservative
measures [13]. Unfortunately DBPC studies on the pre- and/or
post-operative management of such patients are missing.
The endoscopic technique employed for nasal sinus surgery
in non-CF patients is widely standardised and aims to enlarge
the natural sinus opening and remove obstructing polyps. In
contrast to classical functional endoscopic sinus surgery, a
more aggressive approach is used in CF patients. Surgery
also requires meticulous medical aftercare and endoscopic
monitoring. Nevertheless, resection of nasal landmarks such
as the middle or lower turbinate does not alleviate CRS
symptoms.
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Diagram of nasal landmarks (in black) including the oriﬁcium = nasal valve (nv), the superior-, middle-, and lower nasal turbinates (s/m/l nt) and the choanal
area (ch). Nasal ﬂow pattern (in grey) with laminar and turbulent nasal inspiratory ﬂow. A: ﬂow pattern with intact nasal airways achieving maximal contact
of the inspired air to nasal surfaces. B: ﬂow pattern after surgical resection of the middle nasal turbinate resulting in very high ﬂow rates in some areas and
loss of ventilation in others. Adapted from Grützenmacher [46].
On the contrary, this may lead to pathological intranasal
airﬂow patterns (Fig. 1), causing irregular aeration of the
nasal mucosa. Thus, some focal areas of UAW mucosa may
dry out, leading to discomfort and development of nasal crusts
that may further hinder physiological airﬂow patterns.
Because the recurrence rate after ENT surgery is so high,
we suggest that prevention of CRS is as important in CF
as optimization of surgery, and that both require a strategy
for conservative care of the UAW. Standardised prospective
studies of speciﬁc surgical techniques versus outcomes are
required to assess their effectiveness in CF-related polyposis.
4. Discussion and conclusions
The nasal passages and PS are integral parts of the
airways [41]. The strong relationship between CRS and
lung disease emphasises the concept of “united airways”,
which is already accepted in the treatment of common nasal
polyposis [11]. In patients with asthma, pulmonary disease is
much more difﬁcult to stabilize when they have concomitant
CRS [11] and asthma control is signiﬁcantly improved with
medical and/or surgical therapy of UAW disease. The Allergic
Rhinitis and its Impact on Asthma working group [42,43],
in collaboration with the WHO, has issued a state-of-the-art
review and recommendations on the link between rhinitis and
asthma. Similar recommendations have been published for
upper airway involvement in COPD [44].
In CF patients, potential bidirectional communication
between upper and lower airways makes the simultaneous
assessment and treatment of all respiratory disease foci
mandatory [45]. In contrast to asthma and COPD, pulmonary
infection with P.a. plays a central role in the progression of
CF lung disease.
Due to the lack of available evidence, the evaluation of
conservative and surgical therapeutic options for CF-related
CRS requires prospective, blinded studies and systematic
evaluation of conservative UAW treatments to be of maximum
practical utility. This goal can be achieved by integrating
standard criteria for assessing UAW symptoms into routine
patient examinations in CF centres and the development of
guidelines by an interdisciplinary working group comprised
of CF clinicians, otorhinolaryngologists, microbiologists and
other interested specialists.
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